RPI and Kipu Quantum Ran Autism Biomarker Selection on IBM's 120-Qubit Nighthawk Processors: What the 24 September 2026 arXiv Preprint Found
Quentir Medicine Monitor
Evidence-based insights for quantum medicine. Published by Quentir Systems LLC · September 26, 2026.
A blood sample from a young child can yield hundreds of metabolite measurements, while a typical autism biomarker study enrolls a few dozen children. Choosing which handful of those measurements a diagnostic model should rely on is a hard combinatorial search. A team at Rensselaer Polytechnic Institute in Troy, New York, working with the Berlin company Kipu Quantum, posted a paper on arXiv on 24 September 2026 that runs this search on IBM quantum processors.
The paper, "Quantum Feature Selection for Biomedical Data Analysis" by Hongbin Liu, Robert Lahmann, Benjamin Campbell, Zhemin Zhang, Zhiding Liang, Siona Bapat and Juergen Hahn, poses metabolomic feature selection as a binary optimization problem and solves it on two IBM Nighthawk processors, ibm_rensselaer and ibm_miami, each with 120 qubits. The test data come from three published studies, two of blood plasma and one of the gut microbiome, in children with autism spectrum disorder and typically developing peers. The quantum solver picked five-feature subsets that classified about as well as several standard classical methods, and the authors state plainly that their results do not claim a quantum advantage.
For clinicians and hospital laboratories the interest lies in the diagnostic problem underneath. Blood-based autism screening has been studied at least since 2012, when the oldest of the three datasets used here was published, and every such test depends on a short, stable list of markers. This preprint tests whether current quantum hardware can help build that list. It does not test a diagnostic, and it enrolled no new patients.
The work is a first hardware feasibility study on retrospective data. It has not yet been peer reviewed, and its datasets are small: the largest group has 83 children with an autism diagnosis and 76 without.
Why autism diagnosis at around age four drives the search for blood biomarkers
The clinical stakes are real. The Centers for Disease Control and Prevention's Autism and Developmental Disabilities Monitoring Network, in a surveillance report by Kelly Shaw and colleagues published on 17 April 2025, estimated autism prevalence among 8-year-old children at its 16 surveillance sites in the United States in 2022 at 32.2 per 1,000, or about one in 31. The RPI paper cites that figure and adds, from earlier studies, that diagnosis is considered ideal at 18 to 24 months while the average age of diagnosis is about four years. The authors argue that this gap delays support for many children.
The paper presents biomarker-based screening as one route toward earlier and more precise evaluation, citing earlier metabolic studies of children with autism. The statistical difficulty is well known to anyone who has built such a model. With far more measured variables than participants, a classifier can fit noise in the training data and then fail on the next cohort. Selecting a small subset of informative, non-redundant metabolites is the standard defense, and it is also where the computation becomes expensive.
How the RPI and Kipu team turned metabolite selection into a QUBO problem
An exhaustive search checks every possible combination of features. With 56 candidate metabolites and a target of five, that is about 3.8 million subsets, each evaluated with a classifier. The authors instead write the task as a quadratic unconstrained binary optimization problem, or QUBO: each metabolite is a yes-or-no switch, and a single cost function rewards switches for relevance and penalizes pairs that carry the same information.
Their new ingredient is the cost function itself. Relevance is scored with the Fisher score, which measures how well a single metabolite separates the two groups relative to its spread within each group. Redundancy is scored with the covariance between pairs of metabolites. The team compared this "Fisher-covariance" formulation with an existing QUBO based on mutual information, known as MIQUBO. Across three datasets and five classifiers, the new formulation gave better accuracy in 13 of the 15 comparisons. The authors suggest the simpler statistics are more stable on small samples, where mutual information is hard to estimate.
Quantum pillar: computing. Technology readiness: TRL 3 of 9. The method has been shown to run on real quantum processors using previously published, de-identified data from small groups of children, with no new patients, no prospective study and no diagnostic test built from the selected markers yet.
What ran on ibm_rensselaer and ibm_miami, and on which children's data
The three datasets were collected in earlier studies. The first holds 24 plasma measurements from the folate-dependent one-carbon and transsulfuration pathways, from 83 children with autism and 76 typically developing children. The second comes from untargeted plasma metabolomics and the third from gut-microbiome sequencing, each with 18 children with autism and 20 without, and each reduced by statistical prescreening to 56 and 54 features so the problem would fit current hardware. Because the data were already published and de-identified, the authors report that no new ethics review was needed.
Two quantum algorithms were tried. The first, bias-field digitized counterdiabatic quantum optimization, is a sampling method introduced by Kipu Quantum researchers in a 2024 preprint that repeatedly measures the processor and uses the results to steer the next round toward low-cost answers. It ran five iterations of 1,000 measurements each. The second, the better-known Quantum Approximate Optimization Algorithm (QAOA), ran only on the smallest dataset, because on the larger problems its deeper circuits did not converge reliably on the noisy hardware. Across ten repeated QAOA runs the selected subsets varied, while the Kipu method returned the same subsets every time.
The most useful single result is a consistency check. For every dataset, the Kipu Quantum solver chose exactly the same five features as a classical heuristic, iterative tabu search, solving the same QUBO in MATLAB. The quantum processor reached the answer a good classical optimizer also reaches. Classification accuracy was then measured with leave-one-out cross-validation, in which each child is held out in turn and predicted by a model trained on everyone else. Against Pearson-correlation filtering, exhaustive search and recursive feature elimination with support vector machines, the QUBO subsets were competitive and varied less across classifiers, and no single method won on every dataset. The paper standardizes the data inside each cross-validation fold, but it does not state that the prescreening and the feature selection itself were repeated within each fold. If they were run once on all children, the reported accuracies could be somewhat optimistic; the preprint leaves that question open.
What the 490-second and 83-second runtimes do and do not show
The runtime table is where a quick reader could overread the paper. On the 24-feature dataset the quantum workflow took 83 seconds in total, slower than tabu search at about 20 seconds and exhaustive search at about 26. On the 56-feature dataset it took 490 seconds against about 789 for tabu search and 1,741 for exhaustive search, and on the 54-feature dataset 384 seconds against about 1,032 and 1,464. Actual processor time stayed between 30 and 35 seconds throughout; the rest was circuit compilation and queue waiting.
The authors decline to call this a speed-up. The globally optimal subset was not independently known, so no time-to-solution benchmark was possible, and they cite recent work arguing that an advantage claim needs defined problem instances, resources and metrics. That caution fits a wider pattern Quentir has followed, in which IBM's own July 2026 advantage papers built refutation routes into their experiments. It also echoes a Porto and DLR study covered here earlier, in which simulated quantum annealing ranked known drug pairs through the same kind of QUBO objective. In the RPI study and the Porto and DLR study alike, the value so far lies in the QUBO formulation, which classical solvers can use today.
What a hospital laboratory or diagnostics buyer can take from arXiv 2609.30256
Three points follow for readers who evaluate diagnostics. First, the clinically relevant output of this paper is a short list of plasma metabolites and gut-microbiome features for each dataset, and that list could be found without a quantum computer. Any future autism screening panel built on it would be judged, like every laboratory test, on sensitivity, specificity and replication in independent cohorts, none of which this study measures.
Second, the sample sizes are small. Datasets of 38 children are useful for method development and far from what a regulator or a clinical laboratory would need. Third, the real open question is scale. The authors argue that processor time grew little between 24 and 56 features, and that larger feature spaces may favor quantum sampling as hardware improves. That is a hypothesis for the next study to test with a known optimum and a fixed budget of classical and quantum resources.
For families and clinicians dealing with autism assessment today, none of this changes care yet. For research groups designing the next metabolomic cohort, the Fisher-covariance QUBO is a practical, published tool that runs on an ordinary computer and on IBM's current machines alike.
Sources
Primary source: Hongbin Liu, Robert Lahmann, Benjamin Campbell, Zhemin Zhang, Zhiding Liang, Siona Bapat and Juergen Hahn (Rensselaer Polytechnic Institute and Kipu Quantum), arXiv preprint of 24 September 2026. Also drawn on: Kelly A. Shaw and colleagues for the CDC Autism and Developmental Disabilities Monitoring Network (MMWR, 17 April 2025); and Sebastián Romero and colleagues at Kipu Quantum for the bias-field digitized counterdiabatic algorithm (arXiv, 2024); the readiness assessment is this Monitor's own.